Long‑Term Management of Central Retinal Vein Occlusion (CRVO)

Anti‑VEGF Therapy – First‑Line Treatment

• Initiate monthly intravitreal anti‑VEGF injections (ranibizumab 0.5 mg or aflibercept 2 mg) as soon as macular edema causing vision loss is diagnosed; anti‑VEGF is the cornerstone of indefinite CRVO management. [American Academy of Ophthalmology] 1
• Reserve intravitreal corticosteroids only after ≥6 months of inadequate response to anti‑VEGF, when anti‑VEGF is contraindicated, or as rescue therapy. [American Academy of Ophthalmology] 1

Evidence for Corticosteroid Use

• In the SCORE‑CRVO randomized trial, 27 % of eyes receiving intravitreal triamcinolone 1 mg gained ≥3 lines of visual acuity versus 7 % in the observation group (Level I evidence). [American Academy of Ophthalmology] 2
• Corticosteroid therapy carries significant risks of secondary glaucoma and cataract formation; close monitoring for intra‑ocular pressure rise and lens changes is mandatory. [American Academy of Ophthalmology] 2

Monitoring & Surveillance (First 6 Months)

• Perform monthly examinations that include undilated slit‑lamp biomicroscopy and gonioscopy to detect iris or angle neovascularization; approximately 25 % of CRVO eyes develop iris neovascularization, especially in the ischemic subtype. [American Academy of Ophthalmology] 3
• Add pupillary assessment for a relative afferent pupillary defect at each visit. [American Academy of Ophthalmology] 3
• Conduct a dilated fundus examination at every monthly visit. [American Academy of Ophthalmology] 2

Management of Neovascular Complications

• When iris or angle neovascularization is identified, perform immediate complete pan‑retinal photocoagulation (PRP). [American Academy of Ophthalmology] 1
• Monthly undilated gonioscopy should continue for at least 6 months after diagnosis and be maintained after anti‑VEGF discontinuation in ischemic CRVO. [American Academy of Ophthalmology] 1
• Anti‑VEGF agents may be used adjunctively for iris/angle neovascularization, although phase‑3 trial data are lacking. [American Academy of Ophthalmology] 1
• Focal macular laser photocoagulation provides no benefit for CRVO‑related macular edema (CVOS trial, Level I). PRP is reserved only for neovascular complications. [American Academy of Ophthalmology] 1

Systemic Cardiovascular Risk Management

• All CRVO patients should be promptly referred to primary care or internal medicine for aggressive control of cardiovascular risk factors. [American Academy of Ophthalmology] 2
• CRVO is associated with markedly higher mortality than age‑matched controls due to cardiovascular disease and diabetes. [American Academy of Ophthalmology] 3
• Attributable risk estimates: systemic hypertension (≈48 % of RVO), hyperlipidemia (≈20 %), diabetes mellitus (≈5 %); sleep apnea is also linked to CRVO. [American Academy of Ophthalmology] 2 & 3
• Patients have a 1 % annual risk of developing CRVO in the fellow eye; educate them to report any sudden visual change in either eye without delay. [American Academy of Ophthalmology] 3

Long‑Term Follow‑Up Schedule

• Continue monthly visits while active macular edema persists or in eyes with ischemic CRVO; otherwise, a PRN (as‑needed) schedule with visits every 6–8 weeks and OCT monitoring is acceptable. [American Academy of Ophthalmology] 1
• Each follow‑up visit must include: visual acuity assessment, intra‑ocular pressure measurement, slit‑lamp examination with iris inspection, OCT imaging of the macula, and gonioscopy when ischemic CRVO or neovascular risk remains. [American Academy of Ophthalmology] 1

Critical Pitfalls to Avoid

• Do not delay anti‑VEGF treatment awaiting spontaneous improvement; early therapy is essential for optimal visual outcome. [American Academy of Ophthalmology] 3
• Do not miss neovascular glaucoma; monthly gonioscopy during the first 6 months is required. [American Academy of Ophthalmology] 3 & 1
• Do not use corticosteroids as first‑line therapy because of the high risk of intra‑ocular pressure elevation and cataract formation. [American Academy of Ophthalmology] 1
• Do not perform macular laser photocoagulation for CRVO‑related edema; it offers no visual benefit. [American Academy of Ophthalmology] 1
• Do not neglect systemic evaluation; CRVO serves as a marker of underlying systemic vascular disease requiring aggressive risk‑factor modification. [American Academy of Ophthalmology] 2 & 3

Treatment for Retinal Venous Occlusion

Introduction to Treatment

• The American Academy of Ophthalmology recommends anti-VEGF agents as the first-line treatment for macular edema associated with retinal vein occlusion (RVO), as they provide superior visual outcomes compared to other treatment modalities 4, 5, 6

Types of Retinal Vein Occlusion

• Retinal vein occlusion (RVO) is classified based on the location of the obstruction, including central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO), according to the American Academy of Ophthalmology 7

Pathophysiology and Complications

• Risk factors for RVO include older age (>40 years), arteriosclerosis, systemic hypertension, and diabetes, as stated by the American Heart Association 7

Treatment Algorithm for Macular Edema in RVO

• The American Academy of Ophthalmology recommends multiple level I studies that demonstrate the efficacy of anti-VEGF agents in treating macular edema associated with both BRVO and CRVO 5, 6
• FDA-approved options for anti-VEGF agents include ranibizumab and aflibercept, while bevacizumab is used off-label, as approved by the FDA 8
• The BRAVO trial showed that monthly intravitreal ranibizumab injections resulted in significant visual gains (16-18 letters) compared to sham injections (7.3 letters) at 6 months, with a strength of evidence level I 5
• Early treatment with anti-VEGF agents is crucial, as delay in treatment can lead to suboptimal visual outcomes, with a high level of evidence 5

Second-Line Treatment: Intravitreal Corticosteroids

• Intravitreal corticosteroids (triamcinolone and dexamethasone implant) are effective but considered second-line due to significant ocular side effects, such as secondary glaucoma and cataract formation, as reported by the National Eye Institute 8, 9, 7

Third-Line Treatment: Laser Photocoagulation

• Grid laser photocoagulation was historically the standard treatment for macular edema in BRVO, but recent clinical trials (BRIGHTER and RETAIN) demonstrated that adding laser to ranibizumab did not improve visual outcomes or reduce treatment burden, with a strength of evidence level I 10, 9
• The Branch Vein Occlusion Study (BVOS) showed that grid-pattern laser photocoagulation resulted in better visual outcomes than no treatment, with a moderate level of evidence 9

Treatment for Neovascular Complications

• Sectoral panretinal photocoagulation (PRP) is recommended when complications such as vitreous hemorrhage occur in BRVO, as stated by the American Academy of Ophthalmology 9
• Dense peripheral panretinal photocoagulation (PRP) is the best treatment for iris neovascularization or retinal neovascularization in CRVO, with a high level of evidence 6, 8
• PRP decreases the risk of progression to iris neovascularization and may prevent neovascular glaucoma, as reported by the National Eye Institute 6

Follow-up Recommendations

• Monthly follow-up for 6 months in eyes with CRVO and in eyes with ischemic CRVO after discontinuing anti-VEGF to detect neovascularization, as recommended by the American Academy of Ophthalmology 9
• Follow-up evaluations should include visual acuity assessment, undilated slit-lamp biomicroscopy and gonioscopy with careful iris examination, pupillary assessment for relative afferent pupillary defect, intraocular pressure measurement, stereoscopic examination of the posterior pole after pupil dilation, OCT imaging when appropriate, and peripheral retina and vitreous examination when indicated, as stated by the American Academy of Ophthalmology 9, 8, 7, 5, 7, 7, 5

Important Considerations and Pitfalls

• Delay in treatment can lead to poorer visual outcomes, with a high level of evidence 5, 9
• Patients with RVO are at risk for developing RVO in the fellow eye and have higher risk of cardiovascular disease and cerebrovascular accidents, as reported by the American Heart Association 5
• Communication with the primary care physician is essential for management of systemic risk factors, as stated by the American Academy of Ophthalmology 9
• Anti-VEGF agents, laser, and intravitreal steroids are all cost-effective for the management of RVOs, with a moderate level of evidence 5

Guideline for Anti‑VEGF Therapy and Systemic Risk Management in Superotemporal Branch Retinal Vein Occlusion

Initial Ophthalmic Assessment

• Document relative afferent pupillary defect (RAPD) to gauge ischemia severity and the risk of neovascularization. 11
• Perform a dilated fundus examination to identify hemorrhages, cotton‑wool spots, venous dilation/tortuosity, and hard exudates in the superotemporal retinal quadrant. 11, 12
• Use fluorescein angiography to delineate areas of capillary non‑perfusion and to differentiate ischemic from non‑ischemic BRVO. 11

First‑Line Anti‑VEGF Therapy

• Initiate monthly intravitreal anti‑VEGF injections (ranibizumab 0.5 mg or aflibercept 2 mg) promptly when macular edema is causing vision loss, and arrange immediate referral to an internist for aggressive control of hypertension, diabetes, and hyperlipidemia. (Level I evidence – multiple randomized trials) 11, 12, 13
• Anti‑VEGF agents are the safest and most effective first‑line treatment for macular edema associated with BRVO. (Level I) 12, 13
• Bevacizumab, although off‑label, is frequently employed in clinical practice. (Level II – observational data) 11

Second‑Line Intravitreal Corticosteroids (When Anti‑VEGF Inadequate)

• Consider intravitreal triamcinolone acetonide or dexamethasone implant after at least 6 months of insufficient response to anti‑VEGF, contraindication to anti‑VEGF, or as rescue therapy. (Level II) 14
• In the SCORE‑BRVO trial, roughly one‑third of eyes receiving laser, triamcinolone 1 mg, or triamcinolone 4 mg achieved ≥15‑letter visual gains at 12 months. (Level I) 14
• Corticosteroid use carries significant risks of secondary glaucoma (requiring IOP monitoring at every visit) and cataract formation. (Level II) 14, 12

Management of Neovascular Complications

• Apply sectoral pan‑retinal photocoagulation (PRP) to retinal areas of non‑perfusion to lower the risk of vitreous hemorrhage. (Level II) 11
• Use anti‑VEGF agents adjunctively when PRP alone does not adequately control angiogenesis or to facilitate complete laser delivery. (Level II) 11

Systemic Risk‑Factor Management

• Immediate referral to an internist is essential because BRVO is strongly linked to systemic vascular disease. (Level I) 11, 12
• Approximately 48 % of retinal vein occlusions are attributable to hypertension, 20 % to hyperlipidemia, and 5 % to diabetes mellitus. (Epidemiologic data) 14
• Patients with BRVO have an elevated risk of cardiovascular and cerebrovascular events. (Epidemiologic data) 14
• Coordinate care with primary‑care physicians to optimize blood‑pressure control, glycemic targets (e.g., HbA1c), and lipid management. (Level II) 11, 12, 13
• Document the retinal vascular occlusion as end‑organ damage in communications with the primary‑care team to emphasize the urgency of systemic risk‑factor modification. (Level II) 15, 12

Practices to Avoid

• Do not use corticosteroids as first‑line therapy for macular edema due to the heightened risk of intraocular pressure elevation and cataract formation. (Level II) 12, 13
• Do not neglect systemic evaluation; BRVO serves as a marker of underlying systemic vascular disease that requires aggressive risk‑factor modification. (Level II) 14, 12